Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best multibagger penny stocks to invest in. On March 25, Cantor Fitzgerald reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) with a $19 price target.

Pressmaster/Shutterstock.com

The positive stance is in response to the company making significant progress on the development of TSHA-102, an investigational gene transfer therapy in evaluation for Rett syndrome. Chief Executive Officer Sean Noland has already confirmed they are bolstering commercial-readiness efforts ahead of potential registration.

Taysha Gene Therapies has also received FDA clearance to initiate the ASPIRE trial in 3 patients to support a potential broad label in the second quarter. The milestone follows a favorable tolerability profile, continued patient enrollment, and a well-defined regulatory trajectory.

Amid TSHA-102 development progress, Taysha Gene Therapies reported a net loss of $109 million, or $0.34 per share, for the year ended December 31, 2025. It was a significant increase from a net loss of $89.3 million, or $0.36 a share, for the year ended 2024. The wider-than-expected net loss was due to an increase in research and development expenses, which came in at $86.4 million, up from $66 million in 2024.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic central nervous system diseases. Their lead candidate, TSHA-102, uses miRNA-regulatory technology to treat Rett syndrome, aiming to address the disease’s underlying genetic cause.

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.